FILE PHOTO: The Alzheimer’s drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai/Handout via REUTERS/File Photo Post navigation US FDA grants standard approval of Eisai/Biogen Alzheimer’s drug